The iconic rise of Viagra has long been a example of pharmaceutical success, yet its legacy within the broader market now triggers questions about long-term yields . Generic versions are diminishing market share, prompting anxieties that investing in companies significantly dependent to Viagra's former influence could be a problematic strategy, esp